@article{yu_lei_liu_wang_cao_wang_chen_2021, title={Analysis of Remifentanil-Based Fast-Track Anesthesia Combined with Dexmedetomidine for Transthoracic Device Closure of Atrial Septal Defect in Pediatric Patients}, volume={24}, url={https://journal.hsforum.com/index.php/HSF/article/view/3429}, DOI={10.1532/hsf.3429}, abstractNote={<p class="p1"><span class="s1"><strong>Background</strong>: To investigate the safety and efficacy of remifentanil combined with dexmedetomidine in fast-track cardiac anesthesia (FTCA) for transthoracic device closure of atrial septal defect (ASD) in pediatric patients.</span></p> <p class="p1"><span class="s1"><strong>Methods</strong>: A retrospective analysis was performed on 61 cases of children undergoing ASD closure through a small thoracic incision from January 2018 to January 2020. According to whether FTCA was administered, they were divided into group F (fast-track anesthesia, n = 31) and group R (routine anesthesia, n = 30).</span></p> <p class="p1"><span class="s1"><strong>Results</strong>: There was no significant difference in general preoperative data, perioperative hemodynamics, or postoperative pain scores between the 2 groups (P &gt; .05). The postoperative sedation score of group F was higher than that of group R 1 and 4 hours after extubation. Meanwhile, duration of mechanical ventilation and length of postoperative intensive care unit (ICU) stay of group F were significantly shorter than those of group R (P &lt; .05). No serious anesthesia-related complications occurred.</span></p> <p class="p1"><span class="s1"><strong>Conclusion:</strong> Remifentanil combined with dexmedetomidine in FTCA for transthoracic device closure of ASD in pediatric patients is safe and effective, is worthy of clinical promotion, and can benefit more children.</span></p>}, number={2}, journal={The Heart Surgery Forum}, author={yu, ling-shan and lei, yu-qing and liu, jian-feng and wang, jing and cao, hua and wang, zeng-chun and chen, qiang}, year={2021}, month={Mar.}, pages={E233-E238} }